Selective ultra-short-acting beta-blocker esmolol will soon be available in Ukraine

The anesthesiologist and specialist on medical emergency conditions, Cardiologist, Neurologist, Neurosurgeon, General practitioner

Abstract. The data of experimental studies and the experience of many years of clinical use indicate that esmolol is a unique highly effective selective ultra-short-acting beta-1-blocker for parenteral administration. Absence of internal sympathomimetic activity, the beginning of therapeutic action in the first 2 minutes after administration, rapid elimination, independent of the state of liver and kidney function, linearity of pharmacokinetics allow it to be used in urgent therapy of supraventricular tachyarrhythmias and arterial hypertension, in order to accurately monitor the parameters of heart rate and arterial pressure in the perioperative period. Esmolol is characterized by a favo rable safety profile due to the possibility of selecting the most safe and effective dose by titration, as well as by the low incidence and rapid reversibility of serious side effects after dose reduction or after discontinuation of the drug.

Keywords: hemodynamics; supraventricular tachycardia; atrial fibrillation; atrial flutter; arterial hypertension; perioperative period; β1-blockers; esmolol; Bibloc.

21 November, 2017